Future Directions in the Treatment of Osteosarcoma
Top Cited Papers
Open Access
- 15 January 2021
- Vol. 10 (1), 172
- https://doi.org/10.3390/cells10010172
Abstract
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy.Keywords
This publication has 84 references indexed in Scilit:
- Outpatient chemotherapy, family-centered care, electronic information, and education in adolescents and young adults with osteosarcomaClinical Oncology in Adolescents and Young Adults, 2013
- Addition of pamidronate to chemotherapy for the treatment of osteosarcomaCancer, 2010
- Prognostic significance of early lymphocyte recovery in pediatric osteosarcomaPediatric Blood & Cancer, 2010
- Predicting and facilitating survival of pediatric cancer patients: The ALC storyPediatric Blood & Cancer, 2010
- Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcomaCancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Oral etoposide for recurrent/progressive sarcomas of childhoodPediatric Blood & Cancer, 2003
- Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma IntergroupEuropean Journal of Cancer, 2002
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityThe New England Journal of Medicine, 1986
- Etoposide (VP-16–213)The New England Journal of Medicine, 1985